Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Eur J Cancer
2010 Jul 01;4610:1773-80. doi: 10.1016/j.ejca.2010.04.002.
Show Gene links
Show Anatomy links
The biology and treatment of EML4-ALK non-small cell lung cancer.
Sasaki T
,
Rodig SJ
,
Chirieac LR
,
Jänne PA
.
???displayArticle.abstract???
The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.
???displayArticle.pubmedLink???
20418096
???displayArticle.pmcLink???PMC2888755 ???displayArticle.link???Eur J Cancer ???displayArticle.grants???[+]
Ahrendt,
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung.
2001, Pubmed
Ahrendt,
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung.
2001,
Pubmed
Blons,
Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
2006,
Pubmed
Cataldo,
Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue.
1999,
Pubmed
Choi,
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
2008,
Pubmed
Christensen,
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
2007,
Pubmed
Eberhard,
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
2008,
Pubmed
Fukuyoshi,
EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.
2008,
Pubmed
,
Echinobase
Hernández,
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.
1999,
Pubmed
Hsieh,
Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.
2005,
Pubmed
Inamura,
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
2009,
Pubmed
,
Echinobase
Inamura,
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
2008,
Pubmed
,
Echinobase
Koivunen,
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
2008,
Pubmed
Koivunen,
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
2008,
Pubmed
Le Calvez,
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.
2005,
Pubmed
Lin,
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
2009,
Pubmed
,
Echinobase
Martelli,
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
2009,
Pubmed
,
Echinobase
McDermott,
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
2008,
Pubmed
Mino-Kenudson,
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
2010,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Mounawar,
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
2007,
Pubmed
Perner,
EML4-ALK fusion lung cancer: a rare acquired event.
2008,
Pubmed
Rikova,
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
2007,
Pubmed
Rodig,
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
2009,
Pubmed
Schiller,
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
2002,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shaw,
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling.
2001,
Pubmed
Shigematsu,
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
2005,
Pubmed
Shigematsu,
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
2005,
Pubmed
Shih,
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
2006,
Pubmed
Shinmura,
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
2008,
Pubmed
Soda,
A mouse model for EML4-ALK-positive lung cancer.
2008,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Sun,
Lung cancer in never smokers--a different disease.
2007,
Pubmed
Takahashi,
Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
2010,
Pubmed
,
Echinobase
Takeuchi,
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
2008,
Pubmed
Takeuchi,
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
2009,
Pubmed
Tam,
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
2006,
Pubmed
Thun,
The global burden of cancer: priorities for prevention.
2010,
Pubmed
Tokumo,
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
2005,
Pubmed
Tomizawa,
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
2005,
Pubmed
Tracy,
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
2004,
Pubmed
Wong,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
2009,
Pubmed
,
Echinobase
